Andy Trotti

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi Patient-reported outcomes and the evolution of adverse event reporting in oncology
    Andy Trotti
    Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
    J Clin Oncol 25:5121-7. 2007
  2. ncbi TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
    Lancet Oncol 8:613-24. 2007
  3. ncbi A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 58:674-81. 2004
  4. ncbi Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
    Andy Trotti
    Radiation Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Radiother Oncol 66:253-62. 2003
  5. ncbi CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
    Semin Radiat Oncol 13:176-81. 2003
  6. ncbi Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Arch Otolaryngol Head Neck Surg 135:687-92. 2009
  7. ncbi Assessment of toxicity in cooperative oncology clinical trials: the long and short of it
    Clement K Gwede
    Dept. of Interdisciplinary Oncology, University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    J Oncol Manag 11:15-21. 2002
  8. ncbi Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Am J Otolaryngol 30:38-43. 2009
  9. ncbi The evolution and application of toxicity criteria
    Andy Trotti
    H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612-9497, USA
    Semin Radiat Oncol 12:1-3. 2002
  10. ncbi The need for adverse effects reporting standards in oncology clinical trials
    Andy Trotti
    J Clin Oncol 22:19-22. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Patient-reported outcomes and the evolution of adverse event reporting in oncology
    Andy Trotti
    Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
    J Clin Oncol 25:5121-7. 2007
    ..Therefore, care must be used when developing health outcomes and safety data collection plans...
  2. ncbi TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
    Lancet Oncol 8:613-24. 2007
    ....
  3. ncbi A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 58:674-81. 2004
    ..It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM...
  4. ncbi Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
    Andy Trotti
    Radiation Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Radiother Oncol 66:253-62. 2003
    ..While it appears that mucositis may lead to hospitalization and treatment interruptions, its overall impact on outcomes has not been adequately investigated...
  5. ncbi CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
    Semin Radiat Oncol 13:176-81. 2003
    ..This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0...
  6. ncbi Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Arch Otolaryngol Head Neck Surg 135:687-92. 2009
    ..To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas...
  7. ncbi Assessment of toxicity in cooperative oncology clinical trials: the long and short of it
    Clement K Gwede
    Dept. of Interdisciplinary Oncology, University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    J Oncol Manag 11:15-21. 2002
    ..The potential implications for toxicity data management practices, data quality, patient care management and resource utilization are discussed...
  8. ncbi Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Am J Otolaryngol 30:38-43. 2009
    ..Squamous cell carcinoma (SCC) is associated with IP in about 7% of cases. To date, there has been no pooled analysis to formulate a survival outcome associated with this rare condition...
  9. ncbi The evolution and application of toxicity criteria
    Andy Trotti
    H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612-9497, USA
    Semin Radiat Oncol 12:1-3. 2002
    ..Just as the revised CTC has provided a new common standard for the grading of acute effects, a similar effort is needed in the late effects area. The creation of a unified late effects system is under active development...
  10. ncbi The need for adverse effects reporting standards in oncology clinical trials
    Andy Trotti
    J Clin Oncol 22:19-22. 2004
  11. ncbi Complications of radiation therapy for head and neck cancers. The patient's perspective
    Alison M Rose-Ped
    Empirica, Inc, Portland, Ore 97225, USA
    Cancer Nurs 25:461-7; quiz 468-9. 2002
    ..Trends toward more aggressive management of head and neck cancers underscore the need for new and effective therapies for oropharyngeal mucositis occurring in patients receiving radiotherapy...
  12. ncbi Evaluation of new treatments in radiation oncology: are they better than standard treatments?
    Heloisa P Soares
    H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
    JAMA 293:970-8. 2005
    ..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
  13. ncbi Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14
    K Kian Ang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
    J Clin Oncol 23:3008-15. 2005
    ..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...
  14. ncbi Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation
    Yuhchyau Chen
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 64:1442-51. 2006
    ....
  15. ncbi Measurement of quality of life in head and neck cancer patients utilizing the quality of life radiation therapy questionnaire
    Monika Janda
    Department of Radiotherapy and Radiobiology, University Hospital Medical School of Vienna, Austria
    Strahlenther Onkol 178:153-8. 2002
    ..The H&N module is useful for patients undergoing treatment for head and neck cancer...